Share on StockTwits

Boston Scientific Corp. (NYSE:BSX) EVP Michael P. Phalen unloaded 13,500 shares of Boston Scientific Corp. stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.30, for a total value of $179,550.00. Following the sale, the executive vice president now directly owns 87,522 shares in the company, valued at approximately $1,164,043. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

BSX has been the subject of a number of recent research reports. Analysts at Jefferies Group raised their price target on shares of Boston Scientific Corp. from $12.00 to $13.00 in a research note on Wednesday, February 5th. Separately, analysts at Cowen and Company raised their price target on shares of Boston Scientific Corp. from $14.00 to $15.00 in a research note on Friday, January 31st. Finally, analysts at Piper Jaffray upgraded shares of Boston Scientific Corp. from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 21st. They now have a $18.00 price target on the stock, up previously from $12.00. Nine equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Boston Scientific Corp. presently has a consensus rating of “Buy” and an average price target of $12.54.

Boston Scientific Corp. (NYSE:BSX) opened at 13.06 on Thursday. Boston Scientific Corp. has a one year low of $7.07 and a one year high of $14.08. The stock’s 50-day moving average is $13.07 and its 200-day moving average is $11.98. The company’s market cap is $17.359 billion.

Boston Scientific Corp. (NYSE:BSX) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.13 by $0.08. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter in the prior year, the company posted $0.18 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. Analysts expect that Boston Scientific Corp. will post $0.50 EPS for the current fiscal year.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.